FDA approves Roche’s RozlytrekTM (entrectinib) for people with ROS1-positive, metastatic non-small cell lung cancer and NTRK gene fusion-positive solid tumours


You May Also Like

ContraFect Appoints Lisa Ricciardi as Chief Operating Officer

YONKERS, N.Y., Oct. 05, 2017 (GLOBE NEWSWIRE) -- ContraFect Corporation (NASDAQ:CFRX), a biotechnology company ...

Aptose Presents Highlights From CG-806 KOL Event

Dr. Brian Druker Reviews AML and B-cell Cancer Treatment Landscape and Provides Update on ...